

In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 1-18 without prejudice or disclaimer.

Please add the following new claims 19-39 as noted below.

19. (New) A method for treating asthma comprising:

administering to a subject an immunostimulatory oligonucleotide comprising an immunostimulatory motif comprising a 5'-cytosine-guanine-3', wherein the immunostimulatory oligonucleotide is administered without an allergen in an amount effective to treat asthma.

20. (New) The method of claim 19, wherein the subject is selected from the group consisting of human, dog, cat, horse, and cow.

21 (New) The method of claim 19, wherein the immunostimulatory motif comprises a CG flanked by two 5' purines and two 3' pyrimidines.

22. (New) The method of claim 21, wherein the immunostimulatory motif comprises more than one CG dinucleotide.

23. (New) The method of claim 22, wherein the immunostimulatory motif comprises AACGCTCG.

24. (New) The method of claim 21, wherein the immunostimulatory motif comprises the sequence 5'-AACGTT-3'.

25. (New) The method of claim 21, wherein the immunostimulatory motif comprises a nucleotide sequence selected from the group consisting of AGCGTC, GACGTT, GACGTC, AACGTT, and AGCGTT.

26. (New) The method of claim 21, wherein the immunostimulatory motif comprises a nucleotide sequence comprising:

$X_1X_2CG\ X_3X_4$

wherein X_1X_2 is selected from the group consisting of GpG, GpA, and ApA, and X_3X_4 is selected from the group consisting of TpT and CpT.

27. (New) The method of claim 21, wherein the immunostimulatory motif comprises a nucleotide sequence comprising:

$X_1CG\ X_2$

wherein X_1 is selected from the group consisting of G and A, and X_2 is selected from the group consisting of T and C.

28. (New) The method of claim 19, wherein the immunostimulatory oligonucleotide is administered by injection.

29. (New) The method of claim 19, wherein the immunostimulatory oligonucleotide is administered to skin by transdermal route.

30. (New) The method of claim 19, wherein the immunostimulatory oligonucleotide is administered by a route that allows the oligonucleotide to be taken up by the appropriate target cells.

31. (New) The method of claim 30, wherein the target cells are in the airway of the subject.

32. (New) The method of claim 19, wherein the immunostimulatory oligonucleotide is linked to a molecule.

33. (New) The method of claim 32, wherein the molecule is a targeting moiety.

34. (New) The method of claim 32, wherein the molecule interacts with a target cell surface.

35. (New) The method of claim 19, wherein the immunostimulatory oligonucleotide is linked to a target cell specific binding agent.

36. (New) The method of claim 19, further comprising administering an immunotherapeutic agent.
37. (New) The method of claim 19, wherein eosinophil accumulation in lung tissue is reduced.
38. (New) The method of claim 19, wherein inflammation is prevented.
39. (New) The method of claim 19, wherein the subject is a human.